-
Je něco špatně v tomto záznamu ?
Occurrence of serum antibodies against wheat alpha-amylase inhibitor 0.19 in celiac disease
D. Sánchez, S. Štěpánová Honzová, M. Hospodková, I. Hoffmanová, V. Hábová, P. Halada, H. Tlaskalová-Hogenová, L. Tučková
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 1991
Free Medical Journals
od 1998
ProQuest Central
od 2005-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Nursing & Allied Health Database (ProQuest)
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1998
- MeSH
- celiakie krev diagnóza imunologie MeSH
- dospělí MeSH
- imunoglobulin A krev imunologie MeSH
- imunoglobulin G krev imunologie MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- protilátky anti-idiotypické krev imunologie MeSH
- rostlinné proteiny * imunologie MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
The alcohol-soluble fraction of wheat gluten (gliadins) induces in genetically susceptible individuals immunologically mediated celiac disease (CLD). However, gliadins and related cereal proteins are not unique foodstuff targets of CLD patients´ immune system. Non-gluten wheat alpha-amylase inhibitor 0.19 (AAI 0.19) has been found to be capable of activating human monocyte-derived dendritic cells and inducing pro-inflammatory status in intestinal mucosa of patients with celiac disease (CLD). The possible contribution of this reactivity in incomplete remission of CLD patients on a gluten-free diet (GFD) is matter of contention. In an attempt to characterize the antigenicity of AAI 0.19 in patients with active CLD, patients on a GFD and healthy controls we developed ELISA employing wheat recombinant AAI 0.19. Using this test we revealed a significant (P<0.001) elevation of IgA anti-AAI 0.19 antibodies (Ab) in patients with active CLD (12 out of 30 patients were seropositive) but also in CLD patients on a GFD (15/46), in contrast to healthy controls (2/59). Anti-AAI 0.19 IgG Ab levels were increased (P<0.001) only in patients with active CLD (14/30) in contrast to the controls. Interestingly, the levels of anti-AAI 0.19 IgG Ab were decreased in CLD patients on a GFD (P<0.001, 1/46) compared to the controls (1/59). Notably, 20 out of 30 patients with active CLD were positive either for IgA or for IgG anti-AAI 0.19 Ab. Thus, the majority of CLD patients developed a robust IgA and IgG Ab response against AAI 0.19. These findings may contribute to the broadening of the knowledge about CLD pathogenesis.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19004007
- 003
- CZ-PrNML
- 005
- 20190208091451.0
- 007
- ta
- 008
- 190124s2018 xr ad f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.933876 $2 doi
- 035 __
- $a (PubMed)29750882
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Sánchez, Daniel $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic. sanchez@biomed.cas.cz. $7 xx0129504
- 245 10
- $a Occurrence of serum antibodies against wheat alpha-amylase inhibitor 0.19 in celiac disease / $c D. Sánchez, S. Štěpánová Honzová, M. Hospodková, I. Hoffmanová, V. Hábová, P. Halada, H. Tlaskalová-Hogenová, L. Tučková
- 520 9_
- $a The alcohol-soluble fraction of wheat gluten (gliadins) induces in genetically susceptible individuals immunologically mediated celiac disease (CLD). However, gliadins and related cereal proteins are not unique foodstuff targets of CLD patients´ immune system. Non-gluten wheat alpha-amylase inhibitor 0.19 (AAI 0.19) has been found to be capable of activating human monocyte-derived dendritic cells and inducing pro-inflammatory status in intestinal mucosa of patients with celiac disease (CLD). The possible contribution of this reactivity in incomplete remission of CLD patients on a gluten-free diet (GFD) is matter of contention. In an attempt to characterize the antigenicity of AAI 0.19 in patients with active CLD, patients on a GFD and healthy controls we developed ELISA employing wheat recombinant AAI 0.19. Using this test we revealed a significant (P<0.001) elevation of IgA anti-AAI 0.19 antibodies (Ab) in patients with active CLD (12 out of 30 patients were seropositive) but also in CLD patients on a GFD (15/46), in contrast to healthy controls (2/59). Anti-AAI 0.19 IgG Ab levels were increased (P<0.001) only in patients with active CLD (14/30) in contrast to the controls. Interestingly, the levels of anti-AAI 0.19 IgG Ab were decreased in CLD patients on a GFD (P<0.001, 1/46) compared to the controls (1/59). Notably, 20 out of 30 patients with active CLD were positive either for IgA or for IgG anti-AAI 0.19 Ab. Thus, the majority of CLD patients developed a robust IgA and IgG Ab response against AAI 0.19. These findings may contribute to the broadening of the knowledge about CLD pathogenesis.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protilátky anti-idiotypické $x krev $x imunologie $7 D000888
- 650 _2
- $a celiakie $x krev $x diagnóza $x imunologie $7 D002446
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoglobulin A $x krev $x imunologie $7 D007070
- 650 _2
- $a imunoglobulin G $x krev $x imunologie $7 D007074
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a rostlinné proteiny $x imunologie $7 D010940
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Honzová, Stanislava, $d 1953- $7 jn20001103562 $u Synlab czech Ltd., Prague, Czech Republic
- 700 1_
- $a Hospodková, Marie $7 xx0228256 $u synlab czech Ltd., Prague, Czech Republic
- 700 1_
- $a Hoffmanová, Iva $7 xx0101007 $u Second Department of Internal Medicine, Third Faculty of Medicine, Charles University in Pragueand University Hospital Královské Vinohrady, Prague, Czech Republic
- 700 1_
- $a Hábová, Věra. $7 xx0073784 $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the CzechAcademy of Sciences, Prague, Czech Republic
- 700 1_
- $a Halada, Petr, $d 1972- $7 xx0063115 $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the CzechAcademy of Sciences, Prague, Czech Republic
- 700 1_
- $a Tlaskalová, Helena, $d 1938- $7 jn20000402365 $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the CzechAcademy of Sciences, Prague, Czech Republic
- 700 1_
- $a Tučková, Ludmila, $d 1945- $7 xx0036257 $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the CzechAcademy of Sciences, Prague, Czech Republic
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 67, č. 4 (2018), s. 613-622
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29750882 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y 4 $z 0
- 990 __
- $a 20190124 $b ABA008
- 991 __
- $a 20190206110009 $b ABA008
- 999 __
- $a ok $b bmc $g 1374796 $s 1042185
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 67 $c 4 $d 613-622 $e 20180510 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- LZP __
- $b NLK118 $a Pubmed-20190124